Healthcare Value Capital’s Gilead Sciences GILD Stock Holding History

Healthcare Value Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$3.74M	–	22
2020 Q1	$3.74M	Buy	+50,000	New	+$3.45M	6.29%	3
2019 Q4	–	Sell	-50,000	Closed	-$3.17M	–	17
2019 Q3	$3.17M	Sell	50,000 -100,000	-67%	-$6.54M	5.72%	6
2019 Q2	$10.1M	Buy	+150,000	New	+$9.87M	19.01%	1
2018 Q1	–	Sell	-60,000	Closed	-$4.3M	–	10
2017 Q4	$4.3M	Hold	60,000	–	–	13.07%	3
2017 Q3	$4.86M	Hold	60,000	–	–	9.73%	5
2017 Q2	$4.25M	Hold	60,000	–	–	7.63%	6
2017 Q1	$4.08M	Hold	60,000	–	–	6.97%	7
2016 Q4	$4.3M	Buy	60,000 +25,000	+71%	+$1.86M	4.6%	9
2016 Q3	$2.77M	Buy	+35,000	New	+$2.84M	4.39%	9

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare Value Capital's GILD Position: Q3 2021 in Review

Healthcare Value Capital reduced its Gilead Sciences (GILD) stake by 20% in Q3 2021, selling an estimated $1.05M and leaving 60,000 shares worth $4.19M. The position accounts for 8.27% of the portfolio, ranked #1.

Healthcare Value Capital first reported a position in GILD in Q3 2016 and has held it in 20 quarters since. The position peaked at $7.72M in Q3 2018. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

Healthcare Value Capital held 60,000 shares of Gilead Sciences worth $4.19M as of Q3 2021.
Healthcare Value Capital sold 15,000 Gilead Sciences shares in Q3 2021, an estimated $1.05M.
Gilead Sciences made up 8.27% of Healthcare Value Capital's portfolio in Q3 2021, its #1 holding.
Healthcare Value Capital first reported a position in Gilead Sciences in Q3 2016 and has held it in 20 quarters since.
Healthcare Value Capital's Gilead Sciences position peaked at $7.72M in Q3 2018.
1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Healthcare Value Capital's 13F filing for Q3 2021, filed 15 Nov 2021.